Andere talen Innovent Biologics, Inc.

Aandelen

1801

KYG4818G1010

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:13 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
36,15 ^HKD	+6,48%		+4,18%	-15,44%

17/04	Innovent benoemt Dr. Nageatte Ibrahim tot Oncology Chief Medical Officer	CI
02/04	Hutchmed aanvraag voor behandeling van endometriumkanker geaccepteerd voor beoordeling	AN

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	20/02
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	20/02
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	09/02
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Innovent Biologics, Inc.

Aandelen

1801

KYG4818G1010

Andere talen

Filters